Week 9 Cell Free Systems

Cell-Free Protein Synthesis: Questions and Answers

1. Explain the main advantages of cell-free protein synthesis over traditional in vivo methods, specifically in terms of flexibility and control over experimental variables. Name at least two cases where cell-free expression is more beneficial than cell production.

Cell-free protein synthesis, or CFPS, produces proteins outside living cells using the molecular machinery extracted from cells. Compared with traditional in vivo expression, where proteins are produced inside organisms such as E. coli, yeast, or mammalian cells, CFPS offers more flexibility and experimental control.

The main advantage is that the system is open. In living cells, the researcher cannot easily control everything inside the cell because metabolism, growth, toxicity, stress responses, and gene regulation all influence protein production. In a cell-free system, the researcher can directly add DNA, RNA, amino acids, cofactors, energy sources, salts, chaperones, detergents, liposomes, or other molecules. This makes it easier to test variables quickly and systematically.

CFPS is also useful because it avoids problems related to cell viability. Some proteins are toxic to living cells, difficult to fold inside cells, or interfere with the host metabolism. Since CFPS does not require cells to stay alive, it can produce proteins that would otherwise reduce cell growth or kill the host.

Two cases where cell-free expression is more beneficial than cell-based production are:

1. Toxic proteins
   For example, antimicrobial peptides, pore-forming proteins, or regulatory proteins that interfere with cell metabolism can be difficult to produce in E. coli. CFPS allows their production without harming a living host.

2. Membrane proteins or difficult-to-fold proteins
   Membrane proteins often aggregate or are poorly expressed in cells. In CFPS, detergents, nanodiscs, liposomes, or microsomes can be added directly to support proper folding and insertion.

Other useful cases include rapid prototyping of genetic circuits, testing many DNA designs quickly, producing proteins with non-natural amino acids, and screening enzyme variants.

Example of a Useful Synthetic Minimal Cell

Function

A useful synthetic minimal cell could be designed as a smart therapeutic microcell for localized inflammation detection and drug release.

The function of this synthetic cell would be to detect signs of inflammation in the body and respond by releasing an anti-inflammatory molecule only when needed. This would make treatment more precise and reduce side effects compared with systemic drug delivery.

For example, the synthetic minimal cell could be designed to sense inflammatory signals such as TNF-α, IL-6, or high levels of reactive oxygen species, which are often present in inflamed tissues.

What would the synthetic cell do?

The synthetic minimal cell would act like a small programmable therapeutic device. It would circulate or be placed near a target tissue, such as an inflamed joint, damaged muscle, or rehabilitation injury site.

When the synthetic cell detects inflammation, it activates an internal genetic or biochemical circuit. This circuit triggers the production or release of a therapeutic molecule, such as an anti-inflammatory peptide, cytokine inhibitor, or tissue-repair factor.

In simple terms, the synthetic cell would:

1. Sense a disease-related signal.
2. Process the information using a minimal genetic circuit.
3. Respond by producing or releasing a therapeutic output.
4. Stop responding when the inflammatory signal decreases.

Input and Output

Example Scenario

A patient has chronic inflammation in a joint, muscle, or tendon. Instead of taking anti-inflammatory medicine that affects the whole body, synthetic minimal cells could be delivered locally.

When the cells detect high levels of inflammatory molecules, they release a therapeutic protein. When inflammation decreases, the synthetic cells reduce or stop production. This creates a feedback-controlled treatment system.

Why this is useful

This type of synthetic minimal cell could be useful because it allows localized, controlled, and responsive therapy. It could reduce the risk of side effects and avoid unnecessary drug exposure.

It could be especially valuable for:

• Chronic inflammatory diseases
• Arthritis
• Muscle or tendon injuries
• Rehabilitation after trauma
• Smart biomaterials for wearable or implantable therapeutic systems

Summary

The synthetic minimal cell would function as a programmable inflammation-sensing therapeutic system.

Its input would be inflammatory biomarkers such as TNF-α, IL-6, or reactive oxygen species.

Its output would be the controlled release of an anti-inflammatory or tissue-repair molecule.

The goal would be to create a minimal biological system that can sense the body’s condition and respond only when treatment is needed.

2. Describe the main components of a cell-free expression system and explain the role of each component.

A cell-free expression system usually contains the following components:

DNA or mRNA template

This provides the genetic instructions for the protein. DNA templates include a promoter, ribosome binding site or translation initiation sequence, coding sequence, and terminator. In some systems, mRNA can be added directly.

Cell extract

The extract contains the biological machinery needed for transcription and translation. This includes ribosomes, tRNAs, aminoacyl-tRNA synthetases, translation factors, and sometimes RNA polymerases. The extract can come from E. coli, wheat germ, rabbit reticulocytes, insect cells, or mammalian cells.

Amino acids

These are the building blocks used to synthesize the protein.

Energy source

Protein synthesis requires energy, mainly ATP and GTP. The system needs an energy source such as phosphoenolpyruvate, creatine phosphate, glucose, maltodextrin, or other energy-regeneration molecules.

Nucleotides

NTPs such as ATP, GTP, CTP, and UTP are needed for transcription when DNA is used as the template.

Salts and ions

Magnesium, potassium, and other ions are essential for ribosome function, enzyme activity, and RNA stability. Their concentration strongly affects protein yield.

Cofactors and additives

Some proteins require cofactors such as heme, metals, flavins, or disulfide-bond-supporting reagents. Chaperones can also be added to help folding.

Optional components

Depending on the protein, the system may include detergents, liposomes, nanodiscs, microsomes, protease inhibitors, molecular chaperones, or non-natural amino acids.

3. Why is energy provision regeneration critical in cell-free systems? Describe a method you could use to ensure continuous ATP supply in your cell-free experiment.

Energy provision and regeneration are critical because transcription and translation consume large amounts of ATP and GTP. Without continuous energy regeneration, protein synthesis stops quickly because the system runs out of usable energy.

ATP is needed for many steps, including amino acid charging of tRNAs and general enzymatic activity. GTP is especially important during translation elongation and translocation. Since a cell-free reaction is not a living cell with full metabolism, the energy supply must be added externally and maintained during the experiment.

One method to ensure continuous ATP supply is to use an energy-regeneration system. For example:

Phosphoenolpyruvate system

Phosphoenolpyruvate, or PEP, can be added as a high-energy phosphate donor. Enzymes in the extract transfer phosphate groups to regenerate ATP from ADP. This helps maintain ATP levels during the reaction.

Another option is the creatine phosphate and creatine kinase system, where creatine phosphate regenerates ATP from ADP. More modern systems can use glucose, maltodextrin, or 3-phosphoglycerate because they can provide a more stable and less expensive energy supply.

For my own experiment, I would use a glucose or maltodextrin-based energy system if I wanted longer protein expression, because these systems can support more sustained ATP regeneration and are often more affordable.

4. Compare prokaryotic versus eukaryotic cell-free expression systems. Choose a protein to produce in each system and explain why.

Prokaryotic and eukaryotic CFPS systems differ mainly in their translation machinery, folding environment, post-translational modifications, and complexity.

Protein example for prokaryotic CFPS

I would produce a small antimicrobial peptide or a bacterial enzyme in an E. coli CFPS system. For example, a designed peptide such as PiezoTone-His could be produced in this system because it is relatively small and does not require complex eukaryotic modifications. CFPS would also be useful if the peptide is toxic to living E. coli cells.

Protein example for eukaryotic CFPS

I would produce a human membrane receptor or a protein with disulfide bonds in a eukaryotic system. For example, a human G-protein-coupled receptor, or GPCR, would be better suited to a eukaryotic CFPS system supplemented with microsomes, liposomes, or nanodiscs. This is because GPCRs need proper membrane insertion and folding, which are difficult to achieve in a simple bacterial system.

5. How would you design a cell-free experiment to optimize the expression of a membrane protein? Discuss the challenges and how you would address them in your setup.

To optimize the expression of a membrane protein in a cell-free system, I would design the experiment around both expression yield and correct folding.

Target protein

As an example, I would choose a membrane protein such as a GPCR or an ion channel. These proteins are challenging because they contain hydrophobic transmembrane domains that can aggregate if they are not inserted into a membrane-like environment.

Main challenges

The main challenges are:

1. Aggregation of hydrophobic regions
   Membrane proteins can misfold or form aggregates in aqueous solution.

2. Incorrect folding
   The protein may be produced but not adopt its functional structure.

3. Lack of membrane environment
   Many membrane proteins need lipids, detergents, nanodiscs, or microsomes during translation.

4. Low yield
   Membrane proteins are often expressed at lower levels than soluble proteins.

Experimental setup

I would use a eukaryotic or E. coli cell-free system depending on the protein. For a human membrane protein, I would choose a eukaryotic system or an E. coli system supplemented with membrane-mimicking structures.

I would test several conditions in parallel:

The best setup would likely include co-translational insertion into liposomes or nanodiscs. This means the membrane protein is synthesized in the presence of a membrane-like structure, allowing the hydrophobic domains to enter the lipid environment as the protein is being produced.

To evaluate success, I would measure total protein yield, soluble fraction, correct size using SDS-PAGE or Western blot, and function using a ligand-binding or activity assay if available.

6. Imagine you observe a low yield of your target protein in a cell-free system. Describe three possible reasons for this and suggest a troubleshooting strategy for each.

If I observe low yield of my target protein in a cell-free system, I would consider at least three possible causes.

Additional possible reasons

Other causes of low yield include poor mRNA stability, insufficient energy regeneration, missing cofactors, incorrect folding environment, or an overloaded reaction caused by too much DNA template.

A good troubleshooting workflow would be:

1. Test a positive control protein to confirm the CFPS system works.
2. Check DNA quality and template design.
3. Optimize salts, temperature, DNA concentration, and energy source.
4. Add folding aids, cofactors, or membrane-supporting components if needed.
5. Analyze both total protein and soluble/functional protein, because high expression does not always mean correct folding.

Implementation Strategy Analysis

1. Could this be realized by cell-free Tx/Tl alone, without encapsulation?

Partially, but not fully.

Cell-free systems are open-loop. They can produce the protein once, but they cannot sense, decide, and respond autonomously. The sensor-actuator logic requires a living, persistent system.

Key insight: Cell-free would be useful for prototyping the genetic circuit before building the full synthetic cell — which is exactly its strength.

2. Could a genetically modified natural cell do this?

Yes, and this is the closest real-world precedent.

A natural cell such as a T cell or macrophage could be engineered with:

• A cytokine-sensing promoter (e.g. NF-κB responsive) driving IL-10 expression
• This is conceptually similar to CAR-T cell engineering, already in clinical use

Comparison: Synthetic Cell vs. Genetically Modified Natural Cell

The natural cell brings its own metabolism, membrane, and longevity — but host gene regulation, immune responses, and survival pressures interfere with the engineered function.

3. Desired Outcome of Synthetic Cell Operation

The ideal outcome has three layers:

🎯 Therapeutic Outcome

Local inflammation is suppressed at the site of the flare, tissue damage is reduced, and systemic drug exposure is minimized compared to injected biologics.

⚙️ Operational Outcome

The cell reliably switches on above a defined cytokine threshold, produces a sufficient and bounded quantity of anti-inflammatory protein, and switches off when the signal resolves — avoiding chronic immunosuppression.

🔒 Safety Outcome

The cell does not proliferate uncontrollably, does not produce protein constitutively in the absence of signal, and can ideally be cleared or switched off externally if needed.

Conceptual Summary

The synthetic cell behaves like a biological thermostat:

[Cytokine signal rises]
        ↓
[Sensor promoter activates]
        ↓
[IL-10 / IL-1Ra produced and secreted]
        ↓
[Local inflammation suppressed]
        ↓
[Cytokine signal falls → cell returns to quiet state]

This closed-loop design is particularly relevant for chronic inflammatory conditions such as:

• Rheumatoid arthritis
• Inflammatory bowel disease (IBD)
• Psoriasis Where localized, on-demand anti-inflammatory delivery would significantly reduce the side effects associated with systemic biologic therapies.

Synthetic Cell: Full Component Design & Experimental Details

1. Cell Design Components

A. Membrane Composition

The membrane is a giant unilamellar vesicle (GUV) made of four lipids chosen to mimic a mammalian plasma membrane:

B. Encapsulated Contents

C. Why Mammalian Tx/Tl, Not Bacterial

Bacterial (E. coli) CFPS would not work here for three reasons:

1. The NF-κB responsive promoter requires mammalian RNA Pol II and eukaryotic transcription factors — E. coli sigma factors cannot drive it
2. The Tet-ON system (rtTA3 + TRE3G) is designed for mammalian transactivation machinery
3. IL-10 and IL-1Ra are human proteins that benefit from a mammalian co-translational folding environment

D. Communication with the Environment

The lipid bilayer is largely impermeable to cytokines and proteins, so two mechanisms are required:

2. Experimental Details

Full Gene List

How to Measure Function

Note: The macrophage activation assay is the most critical readout. It tests whether the output is biologically active, not just present.

Summary: Signal Flow

[TNF-α / IL-6 in tissue]
        ↓
[TNFR1 / gp130 receptors on membrane surface]
        ↓
[NF-κB pathway activated: IKBKB → IκBα release → RELA/NFKB1 nuclear entry]
        ↓
[NF-κB promoter drives IL10 transcription]
[TRE3G promoter drives IL1RN + EGFP transcription]
        ↓
[Proteins produced by mammalian CFPS machinery]
        ↓
[IL-10 and IL-1Ra exit via α-hemolysin pore]
        ↓
[Local inflammation suppressed]

Bioreactive Architectural Wall Panel: Cell-Free Air Purification Surface

I really got inspired by this paper: and approach of bioinspiration:

Figure 1. Example diagram related to synthetic cells and bioengineering systems. Source: Frontiers in Bioengineering and Biotechnology.

Based on: Ho, Kubušová et al. (2023) — Multiscale design of cell-free biologically active architectural structures, Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2023.1125156

Field: Architecture

One-sentence pitch

A 3D-printed silk fibroin indoor wall panel, built on the multiscale CFPS biopolymer platform demonstrated by Ho et al. (2023), that autonomously detects formaldehyde and VOC off-gassing from furniture and produces a laccase enzyme in situ to oxidatively degrade them — turning the building surface itself into a living air-purification membrane.

How it works

The paper by Ho et al. demonstrates that freeze-dried CFPS pellets can be mechanically attached into 3D-printed foldable fibrous biopolymer lattices — combining silk fibroin and sodium alginate matrices with cell-free transcription-translation machinery across three design scales: microscale expression within the biopolymer matrix, mesoscale variation of porosity and strength within printed lattices, and macroscale folded indoor surfaces at the meter scale. This proposal takes that exact platform and redirects it toward a functional air-quality application.

The wall panel is fabricated by the same extrusion-based additive manufacturing approach, with the biopolymer lattice designed at mesoscale to maximize surface-area-to-volume ratio and air contact. At the microscale, freeze-dried CFPS pellets carry two components:

1. A formaldehyde-responsive biosensor circuit — using the frmR repressor and PfrmA promoter from E. coli
2. A DNA template encoding fungal laccase — lcc2 from Trametes versicolor Laccase is a copper-containing oxidoreductase that degrades formaldehyde, benzene, and other VOCs into non-toxic products. When indoor humidity contacts the biopolymer matrix — as naturally occurs in occupied spaces — it partially rehydrates the CFPS pellets and initiates transcription and translation. If formaldehyde is simultaneously present at the surface, the frmR repressor is inactivated, the PfrmA promoter opens, and laccase is expressed and diffuses outward through the porous lattice into the surrounding air layer.

Societal challenge addressed

Indoor air quality is a recognized public health problem: the EPA estimates that indoor VOC concentrations are routinely 2–5× higher than outdoor levels, driven primarily by off-gassing from furniture, flooring, adhesives, and paints. Formaldehyde is classified as a Group 1 carcinogen by IARC and is present in virtually every modern interior.

Current solutions — activated carbon filters, air purifiers, houseplants — are passive, require maintenance, consume energy, and do not scale to building surfaces. A biologically active architectural surface that responds proportionally to pollutant load and degrades contaminants without electricity or consumables addresses this gap directly, and aligns with the paper’s stated goals of supporting health, resource optimization, and reduction of energy use in the built environment.

Addressing cell-free limitations — grounded in the paper’s framework

Key differences from the paper’s GFP reporter proof-of-concept

The paper uses GFP as a reporter to confirm CFPS compatibility with the biopolymer matrix. This proposal takes the next step: replacing the reporter with a functional enzymatic output (lcc2 laccase) and adding an upstream inducible biosensor circuit (frmR/PfrmA) so that expression is conditional on pollutant detection rather than always-on.

This converts the platform from a demonstrator into a closed-loop sense-and-respond system, which is precisely the trajectory the paper describes as the future direction for bio-interactive architectural structures.

Multiscale design summary

Key genes and components

Signal flow

[Ambient humidity contacts silk fibroin matrix]
             ↓
[CFPS pellets rehydrate → transcription/translation activates]
             ↓
[Formaldehyde / VOC present at panel surface?]
             ↓ Yes
[frmR repressor inactivated → PfrmA promoter opens]
             ↓
[lcc2 laccase synthesized and secreted through lattice pores]
             ↓
[Laccase oxidizes VOCs → non-toxic products]
             ↓
[Indoor air quality improved — no electricity, no maintenance]

References

Ho, G., Kubušová, V., Irabien, C., Li, V., Weinstein, A., Chawla, S., Yeung, D., Mershin, A., Zolotovsky, K., & Mogas-Soldevila, L. (2023). Multiscale design of cell-free biologically active architectural structures. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1125156

Genes in Space — Mock Proposal

Title: Early detection of spaceflight-induced muscle atrophy using cell-free toehold switch biosensors

Tools used: BioBits® cell-free protein expression system · miniPCR® thermal cycler · P51 Molecular Fluorescence Viewer

1. Background

(100 words max)

Spaceflight causes rapid skeletal muscle atrophy — astronauts can lose up to 20% of muscle mass during a 6-month mission. This impairs performance, increases injury risk, and complicates post-flight recovery. Current monitoring relies on infrequent MRI or exercise tests, which cannot track molecular-level changes in real time. On long-duration missions to Mars, detecting early-stage atrophy at the molecular level would enable timely countermeasure adjustments before irreversible mass loss occurs. Understanding the molecular drivers of spaceflight-induced atrophy also informs treatment of age-related muscle loss on Earth, giving this research dual significance for space exploration and human health broadly.

2. Molecular target

(30 words max)

mRNA transcripts of atrogin-1 (FBXO32) and MuRF1 (TRIM63) — E3 ubiquitin ligase genes that are early transcriptional markers of skeletal muscle atrophy — detected in astronaut blood samples.

3. Target relevance

(100 words max)

Atrogin-1 and MuRF1 are the master regulators of the ubiquitin-proteasome pathway that drives muscle protein degradation. Both genes are transcriptionally upregulated within hours of muscle disuse or microgravity exposure, making their mRNA levels sensitive early indicators of atrophy onset — detectable before measurable mass loss occurs. Elevated transcript levels in blood reflect active muscle breakdown signaling. Monitoring these markers longitudinally during a mission would give flight surgeons a real-time molecular window into crew muscle health, enabling proactive rather than reactive adjustment of exercise countermeasures such as resistive training protocols.

4. Hypothesis and reasoning

(150 words max)

We hypothesize that toehold switch biosensors targeting atrogin-1 and MuRF1 mRNA, deployed in a BioBits® freeze-dried cell-free expression system, can detect upregulation of these atrophy markers in astronaut blood during spaceflight — providing an early warning of muscle degradation before clinically detectable mass loss occurs.

Toehold switches are programmable RNA sensors that trigger translation of a GFP reporter only when a complementary target mRNA sequence is present. By encoding atrogin-1- and MuRF1-specific toehold switches into a BioBits® reaction, we create a portable, single-use diagnostic requiring no living cells, no cold chain, and no specialized equipment. A positive GFP signal, read with the P51 Molecular Fluorescence Viewer, indicates active atrophy signaling in that sample. This approach is uniquely suited to spaceflight constraints: the entire assay fits in a small pouch, is stable at room temperature as a lyophilized pellet, and produces a result readable by a non-specialist crew member.

5. Experimental plan

(100 words max)

Samples: Weekly fingerprick blood draws from crew members throughout the mission.

Controls:

• Positive control — synthetic atrogin-1 / MuRF1 mRNA added directly to BioBits® reaction
• Negative control — BioBits® reaction with no RNA added Protocol:

1. Extract total RNA from blood sample
2. Reverse-transcribe and amplify cDNA using miniPCR® with T7 promoter-tagged primers
3. Add amplified product to freeze-dried BioBits® reaction containing toehold switch constructs
4. Incubate 2 hours at 37°C
5. Read GFP fluorescence with P51 Viewer Measurements: Fluorescence intensity proportional to target mRNA abundance, tracked longitudinally across the mission to detect atrophy trajectory.

Experimental workflow summary

[Weekly fingerprick blood sample]
            ↓
[RNA extraction]
            ↓
[miniPCR® — reverse transcription + T7 promoter-tagged cDNA amplification]
            ↓
[BioBits® freeze-dried reaction — atrogin-1 / MuRF1 toehold switch constructs]
     ↑ Positive control: synthetic target mRNA
     ↑ Negative control: no RNA added
            ↓
[Incubate 2 h at 37°C]
            ↓
[P51 Molecular Fluorescence Viewer — GFP readout]
            ↓
[Fluorescence detected → active atrophy signaling → adjust countermeasures]
[No fluorescence → atrophy markers below threshold → continue current protocol]

Key molecular components

Why this works in space